Long-term VIVID-2 data show more than 90% of patients with [...]
Almirall has hosted the fourth edition of ImmunoSkin, its annual [...]
Protagonist Therapeutics has reported new clinical and preclinical data at [...]
Long-term VIVID-2 data show more than 90% of patients with [...]
Almirall has hosted the fourth edition of ImmunoSkin, its annual [...]
Protagonist Therapeutics has reported new clinical and preclinical data at [...]